# Safety, Tolerability and Pharmacokinetic Characteristics Evaluation on DA414

> **NCT06525168** · PHASE1 · RECRUITING · sponsor: **Chendu DIAO Nine Hong Pharmaceutical Factory** · enrollment: 82 (estimated)

## Conditions studied

- Ischemic Stroke

## Interventions

- **DRUG:** DA414 Granules
- **DRUG:** DA414 placebo

## Key facts

- **NCT ID:** NCT06525168
- **Lead sponsor:** Chendu DIAO Nine Hong Pharmaceutical Factory
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-02-06
- **Primary completion:** 2025-09-30
- **Final completion:** 2026-09-30
- **Target enrollment:** 82 (ESTIMATED)
- **Last updated:** 2024-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06525168

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06525168, "Safety, Tolerability and Pharmacokinetic Characteristics Evaluation on DA414". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06525168. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*